Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 80 Paragraph 5 â 6: Difference between revisions
From GxPlex
imported>GxPlexBot Import from GxPlex Excel |
Gxplex admin (talk | contribs) m 1 revision imported  |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{ | {{ReferenceData | ||
| | |has_document=Document:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 | ||
| | |module=5 | ||
| | |unit=5.3.5 | ||
|scope=MD | |||
|doc_part=Article 80 | |||
Paragraph 5 â 6 | Paragraph 5 â 6 | ||
| | |language=EN | ||
| | |entry_by=Florian Adragna | ||
| | |contributors= | ||
|tags=TAG-00284-Pos-ngn ++ TAG-00209-Pos-sch ++ TAG-00212-Inc-nis ++ TAG-00201-Cli-eSt | |||
|tags_display=[[Glossary:TAG-00284-Pos-ngn|Post-market clinical follow-up]], [[Glossary:TAG-00209-Pos-sch|PMS & PMCF]], [[Glossary:TAG-00212-Inc-nis|Incident]], [[Glossary:TAG-00201-Cli-eSt|Clinical investigation]] | |||
 | |comment=PMCF investigations: vigilance provisions apply | ||
|content=5. In the case of PMCF investigations referred to in Article 74(1), the provisions on vigilance laid down in Articles 87 to 90 and in the acts adopted pursuant to Article 91 shall apply instead of this Article. | |||
 | |||
| | |||
| | |||
 | |||
= | |||
5. In the case of PMCF investigations referred to in Article 74(1), the provisions on vigilance laid down in Articles 87 to 90 and in the acts adopted pursuant to Article 91 shall apply instead of this Article. | |||
6. Notwithstanding paragraph 5, this Article shall apply where a causal relationship between the serious adverse event and the preceding investigational procedure has been established. | 6. Notwithstanding paragraph 5, this Article shall apply where a causal relationship between the serious adverse event and the preceding investigational procedure has been established. | ||
}} | |||
Latest revision as of 13:50, 16 July 2026
| Document information | |
|---|---|
| Reference | EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 |
| Validity area | EU |
| Scope(s) | MD |
| Document name | Regulation (EU) 2017/745 - Medical Device Regulation |
| Version / Revision | 20-Mar-2023 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | REGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 5 â Unit 5.3.5 |
| Scope | MD |
| Document part | Article 80
Paragraph 5 â 6 |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Post-market clinical follow-up, PMS & PMCF, Incident, Clinical investigation |
Content
5. In the case of PMCF investigations referred to in Article 74(1), the provisions on vigilance laid down in Articles 87 to 90 and in the acts adopted pursuant to Article 91 shall apply instead of this Article.
6. Notwithstanding paragraph 5, this Article shall apply where a causal relationship between the serious adverse event and the preceding investigational procedure has been established.
